Moreover, multiple pathways in ACC cells, such as glucocorticoid excess or WNT/ß-catenin upregulation are linked to immunoresistance [25–27], which may explain the limited therapeutic effect of PD-1/PD-L1 inhibitors. This evidence concerns the gene CD274 and adrenal cortex carcinoma.